CanSinoBIO's Td5cp booster vaccine clears China regulatory hurdle

As China confronts a twelve-fold surge in pertussis cases — over 470,000 reported in 2024 alone — the country's drug regulator has accepted a priority application for Td5cp, a booster vaccine designed by CanSinoBIO to protect adolescents and adults who have long been left outside the circle of pertussis immunity. The move reflects a quiet but consequential reckoning: that vaccination, long understood as a gift given once in childhood, must be renewed across a lifetime. In accepting this application, China's health establishment is acknowledging both the limits of its past strategy and the shap